CD4 T-Cell Recent Thymic Emigrants (RTE)
T-helper cells (CD4 cells) are white blood cells called lymphocytes and are a part of the cell-mediated immunity response. There are different T-cells that play a part in our immunity and are distinguished by certain receptors or antigens present on their outer membrane. The name CD4 comes from the CD4 receptor on the surface membrane of these cells. The name T-helper cell comes from cell-mediated immunity, where these cells induce an immune response to foreign pathogens or cancer cells. The CD4 T-helper cells provide immunity by activating cells to detect and destroy foreign antigens. CD4 cells are the main target of the HIV virus, which attaches itself to the CD4 receptor, enters the cell, and inactivates it. As the HIV virus replicates and increases, the CD4 cell count will decrease. Once the CD4 cell count decreases below 500 cells/uL (normal healthy adults have >1000 cells/uL), patients will begin to receive anti-viral therapy. If the count falls below 200 cells/uL it is recommended to begin therapy to prevent infection with Pneumocystis jiroveci (previously P. carinii). CD8 cells, also known as T-suppressor cells, will identify and kill cells that are infected with a virus or are abnormal. When the virus enters the cell and begins to replicate and produce new viruses, they leave certain viral fragments behind. The CD8 cells specific for the antigens on these fragments will destroy the cell before it can create more virus. When a patient is having treatment for HIV, it is desirable to have an increase in CD4 and a decrease in CD8. The U.S. Public Health Service recommends CD4 lymphocyte counts be tested every 3 to 6 months in HIV infected individuals. CD4 count shows diurnal variation and is distinctly influenced by cortisol and catecholamine concentration; therefore, it is important to consistently obtain specimens at the same time of day when performing serial monitoring.
- In diagnosis of human immunodeficiency virus infection (HIV)
- Monitoring patients with human immunodeficiency virus infection (HIV)
- Therapy treatment decision-making in patient with human immunodeficiency virus (HIV)
- As an aid in diagnosis of some other immunodeficiencies other than AIDS
- Monitoring transplant patients
Increased in:
- Inflammatory disease
- Autoimmune diseases such as rheumatoid arthritis
- SLE and chronic autoimmune hepatitis
- Type I diabetes mellitus
- Primary biliary cirrhosis
- Atopic dermatitis
- Psoriasis
Decreased in:
- AIDS/HIV infection
- Acute cytomegalovirus (CMV) infection
- Burns
- Graft-versus-host disease
- Sunburn
- Myelodysplastic syndromes
- Acute lymphoblastic leukemia in remission
- Recovery from bone marrow transplantation
- Herpes infection
- Infectious mononucleosis
- Measles
- Ataxia-telangiectasia
CD4: 359 – 1725 cells/mcL (29 – 61%)
Whole blood collected in green top (heparin) or lavender top (EDTA) tube.
Specimens must be kept at room temperature and analyzed within 72 hours of collection in EDTA or within 48 hours in heparin.
Some medications may affect immunophenotyping results and should be listed on the patient test request form.
- Nat Rev Microbiol. 2008 Nov;6(11 Suppl):S7-15. [PMID: 18923413]
- JAMA. 2006;296:827. [PMID: 16905788]
- SADJ. 2001 Dec;56(12):602-5. [PMID: 11887447]
- JAMA. 2006;296:1498. [PMID: 17003398]
- N Engl J Med. 2006;355:1141. [PMID: 16971720] CD4 Count for Monitoring Blood, Mayo Clinic Interpretive Handbook 2007-2008. Rochester: MN (2009).